BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

827 related articles for article (PubMed ID: 20670199)

  • 1. Transdermal hormone therapy and the risk of stroke and venous thrombosis.
    Speroff L
    Climacteric; 2010 Oct; 13(5):429-32. PubMed ID: 20670199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Menopause and stroke and the effects of hormonal therapy.
    Lobo RA
    Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen and progestogen effect on venous thromboembolism in menopausal women.
    Archer DF; Oger E
    Climacteric; 2012 Jun; 15(3):235-40. PubMed ID: 22612609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study.
    Renoux C; Dell'aniello S; Garbe E; Suissa S
    BMJ; 2010 Jun; 340():c2519. PubMed ID: 20525678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update: estrogen and estrogen plus progestin therapy in the care of women at and after the menopause.
    Davey DA
    Womens Health (Lond); 2012 Mar; 8(2):169-89. PubMed ID: 22375720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review.
    Oliver-Williams C; Glisic M; Shahzad S; Brown E; Pellegrino Baena C; Chadni M; Chowdhury R; Franco OH; Muka T
    Hum Reprod Update; 2019 Mar; 25(2):257-271. PubMed ID: 30508190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmenopausal hormone replacement therapy and venous thromboembolism.
    Wu O
    Gend Med; 2005; 2 Suppl A():S18-27. PubMed ID: 16551553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.
    Canonico M; Oger E; Plu-Bureau G; Conard J; Meyer G; Lévesque H; Trillot N; Barrellier MT; Wahl D; Emmerich J; Scarabin PY;
    Circulation; 2007 Feb; 115(7):840-5. PubMed ID: 17309934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen plus progestin and risk of venous thrombosis.
    Cushman M; Kuller LH; Prentice R; Rodabough RJ; Psaty BM; Stafford RS; Sidney S; Rosendaal FR;
    JAMA; 2004 Oct; 292(13):1573-80. PubMed ID: 15467059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hormone therapy and risk for venous thromboembolism in postmenopausal women].
    Lacut K; Oger E
    Rev Prat; 2005 Feb; 55(4):389-92. PubMed ID: 15828617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis.
    Mohammed K; Abu Dabrh AM; Benkhadra K; Al Nofal A; Carranza Leon BG; Prokop LJ; Montori VM; Faubion SS; Murad MH
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4012-20. PubMed ID: 26544651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.
    Scarabin PY; Oger E; Plu-Bureau G;
    Lancet; 2003 Aug; 362(9382):428-32. PubMed ID: 12927428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a place for postmenopausal hormone therapy use in women with lupus?
    Gompel A; Piette JC
    Panminerva Med; 2008 Sep; 50(3):247-54. PubMed ID: 18927529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women.
    Olié V; Canonico M; Scarabin PY
    Curr Opin Hematol; 2010 Sep; 17(5):457-63. PubMed ID: 20601871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on menopausal hormone replacement therapy in women and cardiovascular disease.
    Valdiviezo C; Lawson S; Ouyang P
    Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):148-55. PubMed ID: 23422240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postmenopausal Hormone Therapy and Risk of Stroke: Impact of the Route of Estrogen Administration and Type of Progestogen.
    Canonico M; Carcaillon L; Plu-Bureau G; Oger E; Singh-Manoux A; Tubert-Bitter P; Elbaz A; Scarabin PY
    Stroke; 2016 Jul; 47(7):1734-41. PubMed ID: 27256671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis.
    Rovinski D; Ramos RB; Fighera TM; Casanova GK; Spritzer PM
    Thromb Res; 2018 Aug; 168():83-95. PubMed ID: 29936403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study.
    Canonico M; Fournier A; Carcaillon L; Olié V; Plu-Bureau G; Oger E; Mesrine S; Boutron-Ruault MC; Clavel-Chapelon F; Scarabin PY
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):340-5. PubMed ID: 19834106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmenopausal hormone therapy and risk of stroke: A pooled analysis of data from population-based cohort studies.
    Carrasquilla GD; Frumento P; Berglund A; Borgfeldt C; Bottai M; Chiavenna C; Eliasson M; Engström G; Hallmans G; Jansson JH; Magnusson PK; Nilsson PM; Pedersen NL; Wolk A; Leander K
    PLoS Med; 2017 Nov; 14(11):e1002445. PubMed ID: 29149179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration.
    Połać I; Borowiecka M; Wilamowska A; Nowak P
    Gynecol Endocrinol; 2013 Feb; 29(2):165-8. PubMed ID: 23116237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.